echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > NICE recommends risdiplam to treat spinal muscular atrophy

    NICE recommends risdiplam to treat spinal muscular atrophy

    • Last Update: 2021-12-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    NICE has issued a draft guideline recommending risdiplam (Evrysdi) as part of the Management Access Agreement (MAA) for the treatment of the rare genetic disease spinal muscular atrophy (SMA)
    .


    It is estimated that approximately 1,500 patients in England will benefit from this drug, which can be taken as a syrup at home


    manage

    MAA is a special agreement between NHS England, NHS Improvement and Roche, which allows people to use risdiplam for treatment while collecting more data
    .


    NICE will then decide whether to recommend the NHS routine use of the drug and update the guidelines


    MAA is a special agreement between NHS England, NHS Improvement and Roche, which allows people to use risdiplam for treatment while collecting more data


    There are several types of SMA.
    NICE’s draft guidelines recommend that risdiplam be used for patients who are clinically diagnosed with SMA type 1, 2 or 3, or for patients with pre-symptomatic SMA and the number of surviving motor neurons is 1 to 4 for two months or more.
    Of patients
    .

    diagnosis

    Amanda Pritchard, Chief Executive Officer of NHS England, said: “In the past three years, the NHS has revolutionized the care of SMA patients by ensuring access to three innovative therapies—Spinraza, Zolgensma, and now risdiplam.
    There are no effective drugs
    .


    "

    Risdiplam is a surviving motor neuron 2 directed RNA splicing modifier
    .


    Risdiplam solves the root cause of SMA: the decrease in the number of survival motor neuron (SMN) proteins


    Infect

     

    Original source:

    Original source:

    https:// href="https://" target="_blank" rel="noopener">https:// https:// Leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.